Skip to the beginning of the images gallery

Maraviroc - 98%, high purity , C-C chemokine receptor type 5 antagonist, CAS No.376348-65-1, C-C chemokine receptor type 5 antagonist

Moligand™

≥98%

CAS#: 376348-65-1
Formula: C₂₉H₄₁F₂N₅O
Molecular Weight: 513.67
EC Number: 609-456-0
MDL number: MFCD13188530
PubChem CID: 3002977

Item Number

M125486

Grouped product items
SKU	Size	Availability	Price
M125486-5mg	5mg	In stock	$58.90
M125486-25mg	25mg	In stock	$265.90
M125486-100mg	100mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$616.90

Potent and selective CCR5 antagonist with potent anti-HIV activity

View related series

Anti-infection CCR CCR5 Antagonist GPCR/G Protein HIV Immunology/Inflammation

Basic Description

Synonyms	UK-427857
Specifications & Purity	Moligand™, ≥98%
Biochemical and Physiological Mechanisms	Maraviroc (UK-427857; Selzentry; Celsentri) is a Selective CCR5 antagonist; displays potent anti-HIV-1 activity. Maraviroc (UK-427857; Selzentry; Celsentri) prevents the interaction of HIV-1 gp120 and CCR5 (IC50 = 6.4 nM), inhibiting HIV-1 entry. Maraviro
Legal Information	Sold for only research purposes
Storage Temp	Store at -20°C
Shipped In	Ice chest + Ice pads
Grade	Moligand™
Action Type	ANTAGONIST
Mechanism of action	C-C chemokine receptor type 5 antagonist
Note	Toxic, refer to SDS for further information. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Product Description	Maraviroc has been used as a C-C chemokine receptor type 5 (CCR5-specific) inhibitor in murine monocyte/macrophage cell line J774A.1, porcine uterine luminal epithelial cells and human lung CD4+ T cells.

Names and Identifiers

IUPAC Name	4,4-difluoro-N-[(1S)-3-[(1S,5R)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
INCHI	InChI=1S/C29H41F2N5O/c1-19(2)27-34-33-20(3)36(27)25-17-23-9-10-24(18-25)35(23)16-13-26(21-7-5-4-6-8-21)32-28(37)22-11-14-29(30,31)15-12-22/h4-8,19,22-26H,9-18H2,1-3H3,(H,32,37)/t23-,24+,25?,26-/m0/s1
InChi Key	GSNHKUDZZFZSJB-HLMSNRGBSA-N
Canonical SMILES	CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C
Isomeric SMILES	CC1=NN=C(N1C2C[C@H]3CC[C@@H](C2)N3CC[C@@H](C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C
WGK Germany	1
Alternate CAS	2414315-81-2,376348-65-1
PubChem CID	3002977
MeSH Entry Terms	4,4-difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide;maraviroc;Selzentry;UK 427,857;UK 427857;UK-427,857;UK-427857;UK427,857;UK427857
Molecular Weight	513.67

PubChem CID

Wikipedia

DrugBank Ligand

CAS Registry No.

GPCRdb Ligand

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

7 results found

Lot Number	Certificate Type	Date	Item
K2301452	Certificate of Analysis	Oct 25, 2023	M125486
K2301453	Certificate of Analysis	Oct 25, 2023	M125486
K2301454	Certificate of Analysis	Oct 25, 2023	M125486
J2127239	Certificate of Analysis	Aug 01, 2023	M125486
I2219220	Certificate of Analysis	Jul 21, 2022	M125486
I2219221	Certificate of Analysis	Jul 21, 2022	M125486
I2219222	Certificate of Analysis	Jul 21, 2022	M125486

Safety and Hazards(GHS)

Pictogram(s)	GHS08
Signal	Warning
Hazard Statements	H373:Causes damage to organs through prolonged or repeated exposure H412:Harmful to aquatic life with long lasting effects
Precautionary Statements	P273:Avoid release to the environment. P501:Dispose of contents/container to ... P260:Do not breathe dust/fume/gas/mist/vapors/spray. P319:Get medical help if you feel unwell.
WGK Germany	1

References

1. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C et al.. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.. Antimicrob Agents Chemother, 49 (11): (4721-32). [PMID:16251317] [10.1021/op500134e]
2. Mencarelli A, Cipriani S, Francisci D, Santucci L, Baldelli F, Distrutti E, Fiorucci S. (2016) Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis.. Sci Rep, 6 (13): (30802). [PMID:27492684] [10.1021/op500134e]
3. Takeuchi T, Kameda H. (2012) What is the future of CCR5 antagonists in rheumatoid arthritis?. Arthritis Res Ther, 14 (2): (114). [PMID:22494450] [10.1021/op500134e]
4. Christopoulos A, Changeux JP, Catterall WA, Fabbro D, Burris TP, Cidlowski JA, Olsen RW, Peters JA, Neubig RR, Pin JP et al.. (2014) International union of basic and clinical pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands.. Pharmacol Rev, 66 (4): (918-47). [PMID:25026896] [10.1021/op500134e]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.

Maraviroc - 98%, high purity , C-C chemokine receptor type 5 antagonist, CAS No.376348-65-1, C-C chemokine receptor type 5 antagonist

Basic Description

Product Properties

Associated Targets(Human)

Names and Identifiers

Database links